Contrast‐enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis

MR imaging is becoming increasingly important in the evaluation of multiple sclerosis based on its sensitivity to acute, often subclinical events in the brain and because it provides a basis for measuring the accumulation of disease over time. Contrast-enhanced MR imaging in particular evaluates disease at the fundamental level of events affecting the blood-brain barrier. This review emphasizes (a) recent developments in the use of contrast-enhanced MR imaging as a measure of disease in patient groups and individuals and (b) its emerging role in evaluating new therapies.